A5062235853- Cancer Immunotherapy and Biomarkers
- Renal cell carcinoma treatment
- Cancer Genomics and Diagnostics
- Lung Cancer Treatments and Mutations
- CAR-T cell therapy research
- Monoclonal and Polyclonal Antibodies Research
- Lung Cancer Research Studies
- Pancreatic and Hepatic Oncology Research
- Virus-based gene therapy research
- Computational Drug Discovery Methods
- Renal and related cancers
- Immunotherapy and Immune Responses
- CRISPR and Genetic Engineering
- Click Chemistry and Applications
- HIV Research and Treatment
- Mathematical Biology Tumor Growth
- Melanoma and MAPK Pathways
- Peptidase Inhibition and Analysis
- Economic and Financial Impacts of Cancer
- Cancer Research and Treatments
- Dialysis and Renal Disease Management
- RNA Interference and Gene Delivery
- Ferroptosis and cancer prognosis
- Bioinformatics and Genomic Networks
- Glioma Diagnosis and Treatment
Allogene Therapeutics (United States)
2024
Pfizer (United States)
2016-2023
Research Institute of Dallas
2022
Lankenau Medical Center
2004-2011
University of Arizona
2006
VA Palo Alto Health Care System
2001-2005
Stanford University
2001-2005
Children's Hospital of Los Angeles
1998-1999
University of Southern California
1997-1999
Salk Institute for Biological Studies
1998
In a single-group, phase 1b trial, avelumab plus axitinib resulted in objective responses patients with advanced renal-cell carcinoma. This 3 trial involving previously untreated carcinoma compared the standard-of-care sunitinib.
A high-quality programmed cell-death ligand 1 (PD-L1) diagnostic assay may help predict which patients are more likely to respond anti-programmed cell death-1 (PD-1)/PD-L1 antibody-based cancer therapy. Here we describe a PD-L1 immunohistochemical (IHC) staining protocol developed by Ventana Medical Systems Inc. and key analytical parameters of its use in formalin-fixed, paraffin-embedded (FFPE) samples non-small lung (NSCLC) head neck squamous carcinoma (HNSCC). An anti-human rabbit...
Abstract Immune-checkpoint inhibitors (ICI), although revolutionary in improving long-term survival outcomes, are mostly effective patients with immune-responsive tumors. Most cancer either do not respond to ICIs at all or experience disease progression after an initial period of response. Treatment resistance remains a major challenge and defines the biggest unmet medical need oncology worldwide. In collaborative workshop, thought leaders from academic, biopharma, nonprofit sectors convened...
Embryonal carcinoma (EC) cell lines are models for early cells in mouse embryogenesis. A 300-base pair fragment of the heavy chain enhancer was inactive F9 EC cells, unlike other nonlymphoid where it has significant activity. Alterations octamer motif increased Nuclear extracts from contained an binding protein (NF-A3) that unique to cells; amount NF-A3 decreased upon differentiation. It is proposed represses specific regulatory sequences contain motif. Thus, same DNA sequence mediates...
Abstract Results and conclusions concerning the ability of HIV glycoprotein (gp) 120 to stimulate monokine secretion have been equivocal, based on observations using natural gp120 derived from infected human cells a Chinese hamster ovary (CHO) cell-derived recombinant fusion protein. Current studies were designed determine whether differences in proteins could result failure trigger production. We found that monocytes release TNF-alpha, IL-1 beta, IL-6, granulocyte-macrophage-CSF, this...
3003 Background: Inhibition of the MAPK pathway with dabrafenib (D) and trametinib (T) is efficacious in BRAF-mutant melanoma. MEK inhibitors have also shown activity BRAF WT melanoma, particularly NRAS-mutant tumors. However, most patients (pts) develop resistance to D T. MEDI4736 (M), a human IgG1 mAb that blocks PD-L1 binding PD-1 CD80 high affinity selectivity, has clinical durable responses an acceptable safety profile multiple tumor types. Combined therapy these agents may lead...
3001^ Background: Immune-suppressing molecules such as PD-L1 can be co-opted by cancer cells to suppress the natural immune response cancer. Upregulation of and inhibition antitumor T-cell activation is observed in several tumor types. MEDI4736 a human IgG1 antibody which binds specifically PD-L1, preventing binding PD-1 CD80. Methods: An ongoing phase 1 multicenter, open-label study (NCT01693562) evaluating safety, pharmacokinetics (PK), activity given IV every 2 (q2w) or 3 wks (q3w) 3+3...
Combining an immune checkpoint inhibitor with a targeted antiangiogenic agent may leverage complementary mechanisms of action for the treatment advanced/metastatic hepatocellular carcinoma (aHCC). Avelumab is human anti-PD-L1 IgG1 antibody clinical activity in various tumor types; axitinib selective tyrosine kinase vascular endothelial growth factor receptors 1, 2, and 3. We report final analysis from VEGF Liver 100 (NCT03289533), phase 1b study evaluating safety efficacy avelumab plus...
101 Background: The phase 3 JAVELIN Renal trial in previously untreated patients (pts) with aRCC demonstrated a progression-free survival (PFS) benefit and higher objective response rate A+Ax vs S (Motzer, ESMO 2018; LBA6_PR). Here, we report outcomes from biomarker analyses of baseline tumor samples. Methods: We correlated efficacy the results molecular tissue samples all 886 pts enrolled 101. Nephrectomy or were characterized by immunohistochemistry (CD8 PD-L1), whole-exome sequencing...
Abstract Big data in healthcare can enable unprecedented understanding of diseases and their treatment, particularly oncology. These may include electronic health records, medical imaging, genomic sequencing, payor from pharmaceutical research, wearables, devices. The ability to combine datasets use across many analyses is critical the successful big a concern for those who generate data. Interoperability quality continue be major challenges when working with different datasets. Mapping...
Retroviral vectors based on the Moloney murine leukemia virus (MoMuLV) have shown inconsistent levels and duration of expression as well a propensity for acquisition de novo methylation in vivo . MoMuLV-based are known to contain sequences that capable suppressing or preventing from long terminal repeat. Previously, we constructed series modified retroviral showed they function significantly better than vitro To test efficacy hematopoietic stem cells vivo, examined gene proviral...
3011 Background: Outcomes are poor for patients (pts) with recurrent/metastatic (R/M) SCCHN, and new treatments needed. An ongoing phase I/II, multicenter, open-label study (NCT01693562) is evaluating the safety efficacy of MEDI4736 (M), a human IgG1 mAb that blocks PD-L1 binding to PD-1 CD80 high affinity selectivity, in multiple solid tumor types including SCCHN. expressed SCCHN tumors may be associated response anti-PD-L1 treatment. Methods: Pts R/M an ECOG 0 or 1, without prior...
8021^ Background: Lung cancer is the leading cause of death in both men and women. PD-L1 upregulated NSCLC may be associated with a poor prognosis. MEDI4736 human IgG1 antibody which binds specifically to preventing binding PD-1 CD80. Methods: An ongoing phase 1, multicenter, open-label study (NCT01693562) evaluating safety efficacy administered IV every 2 wks (q2w) or 3 (q3w) using 3+3 dose escalation followed by expansion cohorts. pts were assigned cohorts histology line therapy (including...
4072 Background: Combining an immune checkpoint inhibitor with a targeted antiangiogenic agent may leverage complementary mechanisms of action for treatment advanced/metastatic (a/m) hepatocellular carcinoma (HCC). Avelumab is human anti–PD-L1 IgG1 antibody clinical activity in various tumor types; axitinib tyrosine kinase selective VEGF receptors 1/2/3. Liver 100 (NCT03289533) phase 1b study evaluating safety and efficacy avelumab + treatment-naive patients (pts) HCC; interim results are...